Welcome to our dedicated page for UNITED THERAPEUTICS SEC filings (Ticker: UTHR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
United Therapeutics Corporation filings document an operating biotechnology company with Nasdaq-listed common stock and a public benefit corporation structure. Recent 8-K reports cover quarterly and annual operating results, business updates, clinical-study announcements for Tyvaso and ralinepag, and capital actions such as share repurchase programs and accelerated share repurchase agreements.
Proxy materials describe board elections, director changes, executive compensation, shareholder voting matters and governance practices. The company’s formal disclosures also address its treprostinil-centered pulmonary arterial hypertension business, development programs in pulmonary and transplant-related medicine, and common-stock capital structure.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt reported an exercise-and-sell transaction in the company’s common stock. On July 7, 2026, she exercised 9,500 stock options at an exercise price of $135.42 per share and sold 9,500 shares of common stock in multiple open-market trades at weighted average prices in the mid-$550s to low-$560s.
A footnote states these transactions were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which will continue until the earlier of the exercise of 1,734,410 stock options expiring on March 15, 2027 or December 31, 2026. Following the transactions, Rothblatt directly holds 40,513 common shares and has additional indirect holdings through family trusts and a spouse, as well as stock options on 349,192 underlying shares held indirectly via a family trust.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt reported an exercise-and-sell transaction in company stock. She exercised 9,500 stock options at an exercise price of $135.42 per share and sold 9,500 common shares in open-market trades around $548–$554 per share under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025.
Following these transactions, she directly holds 40,513 common shares and also has substantial indirect interests through family trusts, including stock options on 349,192 underlying shares at an exercise price of $135.42 expiring on March 15, 2027.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt reported a mix of option exercises and share sales in company stock. She exercised 9,500 stock options for common shares at an exercise price of $135.42 per share and sold 9,500 common shares in multiple open-market transactions at weighted average prices generally between about $547.45 and $558.18. Following these transactions, she directly held 40,513 shares of common stock. The filing states that the option exercise and resulting share sales were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which contemplates the potential exercise of up to 1,734,410 stock options expiring on March 15, 2027, and is scheduled to continue until the earlier of that full exercise or December 31, 2026. In addition to direct holdings, Rothblatt has indirect ownership interests through family trusts and a spouse account, and retains stock options held in a family trust covering 349,192 underlying common shares at an exercise price of $135.42 per share expiring on March 15, 2027.
UNITED THERAPEUTICS Corp executive Paul A. Mahon exercised 8,300 stock options and sold 8,300 common shares in pre-planned trades. On the transactions date, he exercised options at a strike price of $146.03 per share and sold the resulting shares in multiple open-market transactions at weighted average prices generally around the mid-$500s per share. The trades were executed under a pre-arranged Rule 10b5-1 plan entered into on August 11, 2025, indicating they were scheduled in advance. Following these transactions, Mahon directly owns 45,172 shares of UNITED THERAPEUTICS common stock.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt reported option exercises and share sales in UTHR stock. On July 1, 2026, she exercised 9,500 stock options at $135.42 per share and received the same number of common shares.
Those 9,500 shares were then sold in a series of open-market transactions at weighted-average prices generally around the mid-$540s per share, with individual trades executed within price ranges from $537.26 to $549.65. Following these transactions, she held 40,513 common shares directly, along with additional indirect holdings through family trusts and her spouse.
The filing notes that this exercise and sale activity was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. The plan is scheduled to continue until the earlier of the exercise of 1,734,410 stock options expiring on March 15, 2027 or December 31, 2026, and a family trust continues to hold 349,192 stock options with a $135.42 exercise price.
Paul Mahon reported intended sales of 8,300 shares via a stock option exercise to be effected on 07/02/2026 for cash. The filing also lists multiple sales of 8,300 shares each on 04/16/2026, 05/07/2026, 05/21/2026, 06/04/2026, and 06/18/2026 with associated proceeds shown in dollars.
United Therapeutics Group filed a Form 144 reporting a proposed sale of 209,000 shares of common stock, described as an exercise of stock options with a sale date of 07/01/2026. The filing lists an aggregate dollar figure of $113,242,470.00 on the same line. The reported sales in the excerpt also show multiple prior 10b5-1 plan sales by Martine Rothblatt of 9,500 shares on numerous dates in April–June 2026.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine A. Rothblatt reported an exercise-and-sell transaction in company stock. On June 30, 2026, she exercised 9,500 stock options at an exercise price of $135.42 per share, acquiring the same number of common shares.
The filing shows open‑market sales of 9,500 common shares that day in multiple trades at weighted average prices generally between about $535.93 and $549.44. These transactions were made under a pre‑arranged Rule 10b5‑1 trading plan adopted on November 7, 2025, which is scheduled to continue until up to 1,734,410 stock options are exercised or until December 31, 2026, whichever occurs first.
After the reported transactions, Rothblatt directly holds 40,513 common shares. She also has additional indirect holdings of common stock and stock options through various family trusts and her spouse’s account, as described in the filing’s ownership footnotes.
United Therapeutics Chairperson & CEO Martine Rothblatt exercised stock options for 9,500 shares of common stock at an exercise price of $135.42 per share, then sold 9,500 shares in multiple open‑market transactions at prices reported between $539.9783 and $548.9605 per share. These transactions were carried out under a pre‑arranged Rule 10b5‑1 trading plan adopted on November 7, 2025. Following the trades, Rothblatt directly holds 40,513 shares of common stock and continues to have substantial indirect holdings through family trusts, as well as stock options held indirectly covering 349,192 underlying shares that expire on March 15, 2027.
United Therapeutics chairperson and CEO Martine Rothblatt exercised 9,500 stock options and sold 9,500 shares of common stock of United Therapeutics on June 26, 2026. The options carried a $135.42 exercise price and were exercised and sold under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025.
The Form 4 shows multiple open-market sale transactions at prices reported around the low to mid $540s to $550s per share. Following these transactions, Rothblatt held 49,373 common shares directly, along with additional indirect holdings through family trusts and her spouse.
The filing also reports a large remaining stock option position held indirectly via a family trust, covering 349,192 underlying shares at a $135.42 exercise price and expiring on March 15, 2027. The footnotes emphasize that these transactions are part of a continuing 10b5-1 plan that may run until the earlier of exercising 1,734,410 options or December 31, 2026.